To determine whether statin treatment in vivo could evidence a therapeutic opportunity to target BRAF-inhibitor resistant melanoma cells, we subjected established tumors from chronic treated BRAF-inhibitor resistant K029A cells (K029A-R), A375P cells (A375P-R) and SKMEL3 cells (SKMEL3-R) to pitavastatin. This evidence concerns the gene BRAF and melanoma.